well, i personally thought Cyrus was quite good - and could have taken us to the promised land in my opinion. he seemed to distill the company goals down to the critical few items (with a solid plan), was making progress on the hold, and was repairing our relationship with the FDA. i'm still puzzled about what happened - I guess the FDA's shennanigans were too much for him. but, add it to the list of things that we've faced as investors in this company.

the key is that Cyrus signed on because of the strong potential he saw in our drug - and he had more knowledge than most. and that's what we have to rely on as we try to attract our next leader - because we clearly don't have a ton of cash to drop on a new CEO at this point.

I'm hopeful that the same narrative that drew Cyrus to CytoDyn can draw in an equally (or more) qualified candidate - ideally before we turn the calendar to October.